|
 The Penn State Pediatric Stem Cell Transplant
Program is involved with
national groups studying stem cell transplant and is a member of the Children's
Oncology Group and Pediatric Blood and Marrow Transplantation Consortium.
The team also conducts research studies on cord blood transplants, sub-myeloablative transplants, and graft versus host disease (GVHD) treatment.
Current open studies
|
Principal Investigator |
Title of Study |
|
Kenneth Lucas, MD |
The Use of Umbilical Cord Blood as a Source of Hematopoietic Stem
Cells. |
|
Kenneth Lucas, MD |
Normal Blood Donor Study. |
|
Kenneth Lucas, MD |
Collection of Bone Marrow, Blood, or Tumor tissue banked through Human
tissue Network for Cryopreservation and Future lab Investigation from
newly diagnosed or relapsed Ewing's Sarcoma & Neuroblastoma.
|
|
Melanie Comito, MD |
Dose intensive Chemotherapy for children less than 10 years of
age - Newly diagnosed with malignant Brain Tumor, |
|
Kenneth Lucas, MD |
A phase I study to examine the toxicity of allogeneic stem
cell transplantation
for Pediatric solid tumors with relapsed or therapy refractory disease. |
|
Melanie Comito, MD |
High dose temozolomide, thiotepa and carboplatin with
autologous stem cell
rescue (ASCR) followed by continuation therapy with 13-cis-retinoic acid
in
patients with recurrent/refractory malignant brain tumors. |
|
Kenneth Lucas, MD |
A Phase I Trial to Examine the Safety, Clinical,
Immunologic and Virologic
Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of
Allogeneic Stem Cell Transplants with Persistent or Therapy Refractory
Infections. |
|
Kenneth Lucas, MD |
A Phase I-II Randomized Trial to Examine the Clinical, Immunologic, and
Virologic Effects of CMV Specific Cytotoxic T Lymphocytes When Used for
Prophylaxis Against CMV Disease in Recipients of Allogeneic, T Cell
Depleted Stem Cell Transplants.
|
|
John Neely, MD |
A Randomized Trial of Sirolimus-Based Graft versus Host Disease
(GVHD) Prophylaxis after Hematopoietic Stem Cell Transplantation
(HSCT) in Relapsed Acute Lymphoblastic Leukemia (ALL). |
For questions about these or other studies, please contact Swati
Shah at (717) 531-6012. Back |
